Join to View Full Profile
3181 Sw Sam Jackson Park Rd, L952Portland, OR 97239
Phone+1 503-494-5596
Fax+1 503-494-3688
Dr. Druker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1984 - 1987
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1981 - 1984
University of California San Diego School of MedicineClass of 1981
Certifications & Licensure
WA State Medical License 2022 - 2027
OR State Medical License 1993 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2007-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Portland Monthly Magazine Castle Connolly, 2011
- Join now to see all
Clinical Trials
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL Start of enrollment: 2014 Apr 24
Publications & Presentations
PubMed
- Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T Swords, Elie Traer
Blood Cancer Journal. 2025-04-03 - A CEBPB/IL-1β/TNF-α Feedback Loop Drives Drug Resistance to Venetoclax and MDM2 Inhibitors in Monocytic Leukemia.Basil Allen, Daniel Bottomly, Thomas Köhnke, Anthony Wang, Hsin-Yun Lin
Blood. 2025-02-26 - Oncogenicmutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia.Sunil K Joshi, Ariane Huang, Janét Pittsenbarger, Ujwal Shinde, Camilo Posso
Haematologica. 2025-02-13
Journal Articles
- CRISPR-Cas9–Mediated Saturated Mutagenesis Screen Predicts Clinical Drug Resistance with Improved AccuracyRichard D Press, Brian J Druker, Michael R Green, Proceedings of the National Academy of Sciences
Press Mentions
Caught in the Crossfire: The Critical Threats Facing Cancer Centers, Research, and Patient CareMarch 21st, 2025- AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer ResignsDecember 5th, 2024
- Dr. Brian Druker Announces His Resignation as OHSU Knight Cancer Institute CEODecember 3rd, 2024
- Join now to see all
Grant Support
- Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemiaOREGON HEALTH & SCIENCE UNIVERSITY2022–2027
- Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemiaOREGON HEALTH & SCIENCE UNIVERSITY2022–2027
- Architecture and Trajectory of Acquired Resistance to Therapy in AMLOREGON HEALTH & SCIENCE UNIVERSITY2017–2027
- Architecture and Trajectory of Acquired Resistance to Therapy in AMLOREGON HEALTH & SCIENCE UNIVERSITY2017–2027
- Architecture and Trajectory of Acquired Resistance to Therapy in AMLOREGON HEALTH & SCIENCE UNIVERSITY2017–2027
- Knight Scholars Program - Building STEM Interest and Capacity for Cancer Research Careers among Underrepresented and Rural High School StudentsOREGON HEALTH & SCIENCE UNIVERSITY2018–2025
- Chronic Myelogenous Leukemia And BCR-ABL SubstratesNational Cancer Institute2011–2012
- Senior LeadershipNational Cancer Institute2011
- Protocol Specific Research SupportNational Cancer Institute2011
- Protocol Review &Monitoring SystemNational Cancer Institute2011
- Proteomics Shared ResourceNational Cancer Institute2011
- Program Planning And EvaluationNational Cancer Institute2011
- Program LeadershipNational Cancer Institute2011
- Histapathology &Cancer Genotyping Shared ResourceNational Cancer Institute2011
- Flow Cytometry Shared ResourceNational Cancer Institute2011
- Developmental FundsNational Cancer Institute2011
- Data Safety Monitoring SystemsNational Cancer Institute2011
- Clinical Research Management Shared ResourceNational Cancer Institute2011
- Bioanalytical/Pharacokinetic Shared ResourceNational Cancer Institute2011
- AdministrationNational Cancer Institute2011
- Ohsu Knight Cancer InstituteNational Cancer Institute2009–2011
- Ohsu Knight Cancer Institute- Community Health Educator SupplementNational Cancer Institute2010
- Ohsu Knight Cancer Institute - Rapid SupplementNational Cancer Institute2010
- Accelerating Target Identification And Validation In Leukemia: Integrating Sirna-National Cancer Institute2009–2010
- Chronic Myelogenous Leukemia And BCR-ABL SubstratesNational Cancer Institute1995–2009
- Ohsu Cancer InstituteNational Cancer Institute2007–2008
- Cancer And KinasesNational Cancer Institute2005
- CBL Function In Cellular Signaling And TransformationNational Cancer Institute1999–2003
- Tyrosine Kinase Inhibitors As Antineoplastic AgentsNational Cancer Institute1999–2001
- Genetic Analysis Of The Activation Of A Tyrosine KinaseNational Cancer Institute1993–1994
- Genetic Analysis Of The Activation Of A Tyrosine KinaseNational Cancer Institute1990–1992
- Mutagenesis Of Polyoma Middle-T AntigenNational Cancer Institute1986
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
